Skip to main content

Table 4 Results of univariate log-rank analysis of prognostic factors for progression-free survival and overall survival in 162 smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with TPF

From: Betel nut chewing history is an independent prognosticator for smoking patients with locally advanced stage IV head and neck squamous cell carcinoma receiving induction chemotherapy with docetaxel, cisplatin, and fluorouracil

Factors No. of patients Progression-free survival (PFS) Overall survival (OS)
2-year PFS rate (%) P value 2-year OS rate (%) P value
Age      
<53 years old 81 40 0.13 47 0.30
53 years old 81 46   56  
Clinical 7th AJCC stage      
IVA 80 46 0.62 58 0.30
IVB 82 41   45  
Clinical T classification      
T1 ~ 4a 92 44 0.77 55 0.49
T4b 70 42   46  
Clinical N classification      
N0/1 48 60 0.012* 69 0.003*
N2/3 114 36   44  
Primary tumor site      
Oral cavity 62 39 0.19 44 0.18
Others 100 46   56  
Primary tumor site      
Oropharynx 60 45 0.65 55 0.42
Others 102 42   49  
Primary tumor site      
Hypopharynx/Larynx 36 50 0.28 61 0.36
Others 126 41   48  
Alcohol      
Absent 16 56 0.25 69 0.29
Present 146 42   49  
Betel nut chewing      
Absent 31 67 0.004* 71 0.017*
Present 131 37   47  
  1. TPF docetaxel, cisplatin, and fluorouracil
  2. *Statistically significant